Sign in to fuzzto save your conversations, follow your research and come back anytime.

‌

‌
‌

‌
‌
‌

‌
‌

‌

‌
‌
‌
‌
‌
‌
‌

‌
‌
‌
‌
‌
‌

Blue Jet Healthcare Stock Price - ₹579.00 | Healthcare | askfuzz

B

Blue Jet Healthcare

BLUEJET•

NSE

BSE

SectorHealthcare

‌
‌
‌

₹579.00

-₹125.25(17.75%)•Past Year

Loading chart…

‌
‌
‌

‌
‌
‌

In the news

Blue Jet Healthcare May Rally 22% Says Motilal Oswal

Blue Jet Healthcare May Rally 22% Says Motilal Oswal

Blue Jet Healthcare Q1 Results: ₹783M profit decline amid 17.4% revenue drop

Blue Jet Healthcare Q1 Results: ₹783M profit decline amid 17.4% revenue drop

Blue Jet Healthcare shares rally 9% post ₹800 cr QIP allotment

Blue Jet Healthcare shares rally 9% post ₹800 cr QIP allotment

Blue Jet Healthcare gains 8% post Q4 results; analysts split

Blue Jet Healthcare gains 8% post Q4 results; analysts split

Blue Jet Healthcare shares surge 10% post Q4 results beat

Blue Jet Healthcare shares surge 10% post Q4 results beat

Blue Jet Healthcare surges 10% on ₹10,000 cr fundraise approval

Blue Jet Healthcare surges 10% on ₹10,000 cr fundraise approval

Blue Jet Healthcare board approves ₹10,000 cr fund raise amid Q4 profit drop

Blue Jet Healthcare board approves ₹10,000 cr fund raise amid Q4 profit drop

Blue Jet Healthcare Q4 profit drops 41.5%, stock gains 10%

Blue Jet Healthcare Q4 profit drops 41.5%, stock gains 10%

ICICI Securities recommends Blue Jet Healthcare buy at ₹500 target

ICICI Securities recommends Blue Jet Healthcare buy at ₹500 target

Blue Jet Healthcare Q3: Shares hit 52-week low on margin woes

Blue Jet Healthcare Q3: Shares hit 52-week low on margin woes

The Quarter story

The two most recent quarterly results, compared side-by-side.

Blue Jet Healthcare shows strong profit recovery and rising domestic investor interest, though foreign stake declines and pharma segment sales remain volatile.

DII stake grows from 3.6% in Q2 FY26 to 9.1% in Q1 FY27 — strong domestic institutional confidence

FII stake falls from 1.9% in Q1 FY26 to 0.6% in Q1 FY27 — sustained foreign investor exit

EBITDA rebounds from ₹469 Cr in Q3 FY26 to ₹981 Cr in Q1 FY27 — restored operational profitability

Pharma intermediates revenue drops from ₹2,955 Cr in Q3 FY26 to ₹1,210 Cr in Q1 FY27 — volatile order cycles

PAT margin recovers from 20.9% in Q3 FY26 to 26.7% in Q1 FY27 — improved bottom-line efficiency

Promoter shareholding declines from 86.0% in Q1 FY26 to 73.2% in Q1 FY27 — gradual insider dilution

High-intensity sweeteners revenue climbs from ₹257 Cr in Q3 FY26 to ₹397 Cr in Q1 FY27 — strong product recovery

Total expenses rise from ₹1,455 Cr in Q3 FY26 to ₹1,950 Cr in Q1 FY27 — scaled operational spend

Free float market cap rises from ₹1,857 Cr in Q3 FY26 to ₹2,670 Cr in Q1 FY27 — stronger market valuation

Contrast media revenue slips from ₹1,244 Cr in Q3 FY26 to ₹1,159 Cr in Q1 FY27 — softer segment demand